Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desoximetasone
Drug ID BADD_D00620
Description A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status approved
ATC Code D07AC03; D07XC02
DrugBank ID DB00547
KEGG ID D03697
MeSH ID D003899
PubChem ID 5311067
TTD Drug ID D0CZ1Q
NDC Product Code 45802-496; 51672-5204; 63629-8642; 68180-949; 70771-1166; 40032-024; 0168-0180; 70771-1437; 50090-5571; 51672-1270; 51672-1396; 63187-646; 71205-271; 64980-326; 51672-1261; 0472-0478; 72578-091; 0168-0151; 45802-495; 63629-8702; 68180-946; 68180-948; 0472-0479; 68180-950; 68462-531; 22552-0008; 51672-5202; 51672-5205; 51672-5281; 63629-8641; 64980-327; 72578-095; 51672-1352; 51672-5203; 53002-9280; 46439-8706; 51927-0187; 51672-1271; 51672-5263; 68180-944; 82298-112; 45802-807; 51672-1262
UNII 4E07GXB7AU
Synonyms Desoximetasone | Desoxymethasone | 17-Desoxymethasone | 17 Desoxymethasone | Deoxydexamethasone | Topicort | Stiedex | A-41304 | A 41304 | A41304 | Ibaril | Topisolon | Flubason | Topicorte | Desoxi
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 140218-14-0
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental disorder19.07.01.002---
Spinal disorder15.02.04.023---
Therapeutic reaction time decreased08.06.01.015---
Decreased appetite08.01.09.028; 14.03.01.005--
Adverse drug reaction08.06.01.009---
Disease recurrence08.01.03.050---
Drug intolerance08.06.01.013---
Obstruction08.01.03.023---
Pigmentation disorder23.05.03.001---
Sinus disorder22.04.06.002--
Unevaluable event08.01.03.051---
Poor quality sleep17.15.04.002; 19.02.05.005---
Increased bronchial secretion22.12.01.002---
Increased upper airway secretion22.12.03.007---
Gastrointestinal inflammation07.08.03.007---
Infusion site extravasation08.02.05.007; 12.07.05.008--
Bronchial disorder22.03.02.009---
Treatment failure08.06.01.017---
Gastrointestinal sounds abnormal07.01.01.002---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Faeces soft07.01.03.008---
Anal incontinence07.01.06.029; 17.05.01.021--
Tachyphrenia17.03.03.007; 19.10.03.010---
Skin plaque23.03.03.044---
Sensitivity to weather change08.01.03.077---
Increased viscosity of upper respiratory secretion22.12.03.008---
Vein rupture12.01.11.011; 24.03.02.032---
Anal fissure haemorrhage07.12.03.010; 24.07.02.061---
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.002---
Electric shock sensation08.06.02.023; 17.02.07.024---
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages